Zhao Li, Chen Yi, Xia Fangzhen, Abudukerimu Buatikamu, Zhang Wen, Guo Yuyu, Wang Ningjian, Lu Yingli
Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2018 May 17;9:233. doi: 10.3389/fendo.2018.00233. eCollection 2018.
In addition to improving glucose metabolism, liraglutide, a glucagon-like peptide-1 receptor agonist, has weight-loss effects. The underlying mechanisms are not completely understood. This study was performed to explore whether liraglutide could lower weight by modulating the composition of the gut microbiota in simple obese and diabetic obese rats. In our study, Wistar and Goto-Kakizaki (GK) rats were randomly treated with liraglutide or normal saline for 12 weeks. The biochemical parameters and metabolic hormones were measured. Hepatic glucose production and lipid metabolism were also assessed with isotope tracers. Changes in gut microbiota were analyzed by 16S rRNA gene sequencing. Both glucose and lipid metabolism were significantly improved by liraglutide. Liraglutide lowered body weight independent of glycemia status. The abundance and diversity of gut microbiota were considerably decreased by liraglutide. Liraglutide also decreased obesity-related microbial phenotypes and increased lean-related phenotypes. In conclusion, liraglutide can prevent weight gain by modulating the gut microbiota composition in both simple obese and diabetic obese subjects.
除了改善葡萄糖代谢外，胰高血糖素样肽-1受体激动剂利拉鲁肽还具有减肥作用。其潜在机制尚未完全明确。本研究旨在探讨利拉鲁肽是否可通过调节单纯性肥胖和糖尿病肥胖大鼠的肠道微生物群组成来减轻体重。在我们的研究中，将Wistar大鼠和Goto-Kakizaki（GK）大鼠随机给予利拉鲁肽或生理盐水治疗12周。测定生化参数和代谢激素。还用同位素示踪剂评估肝脏葡萄糖生成和脂质代谢。通过16S rRNA基因测序分析肠道微生物群的变化。利拉鲁肽显著改善了葡萄糖和脂质代谢。利拉鲁肽降低体重，且与血糖状态无关。利拉鲁肽使肠道微生物群的丰度和多样性显著降低。利拉鲁肽还减少了与肥胖相关的微生物表型，并增加了与瘦相关的表型。总之，利拉鲁肽可通过调节单纯性肥胖和糖尿病肥胖受试者的肠道微生物群组成来预防体重增加。
